The economic impact of Type 2 diabetes is staggering. The time for half-measures and incremental change is long past.

The health innovation paradox – breakthrough medications and dedicated providers. We spend more and live fewer years than other nations.

Drugs in the GLP-1 category are now being seen in a different light beyond that of weight control, and their promise is fascinating.

Obesity has become a global health crisis, with an estimated 16% of the world’s adult population classified as obese. The search for effective treatments is more urgent than ever.